Research Articles

Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses

Dengue fever, caused by four serotypes of a mosquito-borne virus, is a growing problem in tropical countries. Currently, there is no treatment or vaccine. We evaluated safety and immunogenicity of two doses, given six months apart, of seven formulations of dengue tetravalent live-attenuated vaccine (containing different concentrations of the component viruses) versus placebo in 59 flavivirus-seronegative Thai adults. The first dose was the more reactogenic. Most volunteers experienced clinically moderate fever, headache, myalgia, eye pain or rash 7-11 days after injection, generally lasting three days or less. Modest decreases in platelets and neutrophils were observed. After one dose, 58% of dengue recipients seroconverted (neutralizing antibody level > or = 1:10) against > or = 3 serotypes; 35% seroconverted against all four. After the second dose, seroconversion was 76% and 71%, respectively. All subjects seroconverted to serotype 3 after one dose. Serotype 4 elicited the lowest primary response but the highest increase in seroconversion after the second dose.

This article has been cited by other articles:

				K. Raviprakash, D. Wang, D. Ewing, D. H. Holman, K. Block, J. Woraratanadharm, L. Chen, C. Hayes, J. Y. Dong, and K. Porter A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue Virus J. Virol., July 15, 2008; 82(14): 6927 - 6934. [Abstract] [Full Text] [PDF]

				S. Simasathien, S. J. Thomas, V. Watanaveeradej, A. Nisalak, C. Barberousse, B. L. Innis, W. Sun, J. R. Putnak, K. H. Eckels, Y. Hutagalung, et al. Safety and Immunogenicity of a Tetravalent Live-attenuated Dengue Vaccine in Flavivirus Naive Children Am J Trop Med Hyg, March 1, 2008; 78(3): 426 - 433. [Abstract] [Full Text] [PDF]

				L. Chen, D. Ewing, H. Subramanian, K. Block, J. Rayner, K. D. Alterson, M. Sedegah, C. Hayes, K. Porter, and K. Raviprakash A Heterologous DNA Prime-Venezuelan Equine Encephalitis Virus Replicon Particle Boost Dengue Vaccine Regimen Affords Complete Protection from Virus Challenge in Cynomolgus Macaques J. Virol., November 1, 2007; 81(21): 11634 - 11639. [Abstract] [Full Text] [PDF]

				M. Simmons, K. R. Porter, C. G. Hayes, D. W. Vaughn, and R. Putnak Characterization of Antibody Responses to Combinations of a Dengue Virus Type 2 DNA Vaccine and Two Dengue Virus Type 2 Protein Vaccines in Rhesus Macaques J. Virol., October 1, 2006; 80(19): 9577 - 9585. [Abstract] [Full Text] [PDF]

				P. CHANTHAVANICH, C. LUXEMBURGER, C. SIRIVICHAYAKUL, K. LAPPHRA, K. PENGSAA, S. YOKSAN, A. SABCHAREON, and J. LANG IMMUNE RESPONSE AND OCCURRENCE OF DENGUE INFECTION IN THAI CHILDREN THREE TO EIGHT YEARS AFTER VACCINATION WITH LIVE ATTENUATED TETRAVALENT DENGUE VACCINE. Am J Trop Med Hyg, July 1, 2006; 75(1): 26 - 28. [Abstract] [Full Text] [PDF]

				C. Y.-H. Huang, S. J. Silengo, M. C. Whiteman, and R. M. Kinney Chimeric Dengue 2 PDK-53/West Nile NY99 Viruses Retain the Phenotypic Attenuation Markers of the Candidate PDK-53 Vaccine Virus and Protect Mice against Lethal Challenge with West Nile Virus J. Virol., June 15, 2005; 79(12): 7300 - 7310. [Abstract] [Full Text] [PDF]

				J. E. Blaney Jr., J. M. Matro, B. R. Murphy, and S. S. Whitehead Recombinant, Live-Attenuated Tetravalent Dengue Virus Vaccine Formulations Induce a Balanced, Broad, and Protective Neutralizing Antibody Response against Each of the Four Serotypes in Rhesus Monkeys J. Virol., May 1, 2005; 79(9): 5516 - 5528. [Abstract] [Full Text] [PDF]

				W. D. Crill and G.-J. J. Chang Localization and Characterization of Flavivirus Envelope Glycoprotein Cross-Reactive Epitopes J. Virol., December 15, 2004; 78(24): 13975 - 13986. [Abstract] [Full Text] [PDF]

				J. E. BLANEY JR., C. T. HANSON, C.-Y. FIRESTONE, K. A. HANLEY, B. R. MURPHY, and S. S. WHITEHEAD GENETICALLY MODIFIED, LIVE ATTENUATED DENGUE VIRUS TYPE 3 VACCINE CANDIDATES Am J Trop Med Hyg, December 1, 2004; 71(6): 811 - 821. [Abstract] [Full Text] [PDF]

				G N Malavige, S Fernando, D J Fernando, and S L Seneviratne Dengue viral infections Postgrad. Med. J., October 1, 2004; 80(948): 588 - 601. [Abstract] [Full Text] [PDF]

				F. Guirakhoo, Z. Zhang, G. Myers, B. W. Johnson, K. Pugachev, R. Nichols, N. Brown, I. Levenbook, K. Draper, S. Cyrek, et al. A Single Amino Acid Substitution in the Envelope Protein of Chimeric Yellow Fever-Dengue 1 Vaccine Virus Reduces Neurovirulence for Suckling Mice and Viremia/Viscerotropism for Monkeys J. Virol., September 15, 2004; 78(18): 9998 - 10008. [Abstract] [Full Text] [PDF]

				F. Guirakhoo, K. Pugachev, Z. Zhang, G. Myers, I. Levenbook, K. Draper, J. Lang, S. Ocran, F. Mitchell, M. Parsons, et al. Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman Primates J. Virol., May 1, 2004; 78(9): 4761 - 4775. [Abstract] [Full Text] [PDF]

				S. Jaiswal, N. Khanna, and S. Swaminathan Replication-Defective Adenoviral Vaccine Vector for the Induction of Immune Responses to Dengue Virus Type 2 J. Virol., December 1, 2003; 77(23): 12907 - 12913. [Abstract] [Full Text] [PDF]

				C. Y.-H. Huang, S. Butrapet, K. R. Tsuchiya, N. Bhamarapravati, D. J. Gubler, and R. M. Kinney Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development J. Virol., November 1, 2003; 77(21): 11436 - 11447. [Abstract] [Full Text] [PDF]